Amplifications of cyclin E1 (CCNE1) are present in 25% of high-grade serous ovarian cancers and are associated with poor survival and impart resistance to CDK2 inhibitors (144) (Table 1). The gene discussed is CCNE1; the disease is ovarian serous adenocarcinoma.